The p53 gene is currently thought to be a tumor suppressor gene, and its alterations have been suggested to be involved in the pathogenesis of several human malignancies, including some leukemias and lymphomas. We present here evidence for the possible involvement of p53 gene mutations in the myelodysplastic syndrome (MDS), although the incidence is relatively low. Forty-four patients with MDS and six patients with overt leukemias that developed from MDS were studied for p53 gene alterations using reverse transcriptase-polymerase chain reaction, single-strand conformation polymorphism analysis, and nucleotide sequencing. Three patients with MDS (2 RAEB and 1 RAEB YELODYSPLASTIC syndrome (MDS) is a group of M clonal proliferative disorders of the bone marrow characterized by dyshematopoiesis and peripheral blood cytopenias."' MDS is presumed to be a preleukemic state, and approximately 40% of patients with MDS develop leukemia~.'.~ We previously reported the significance of mutations in the N-ras oncogene in the progression from MDS to overt l e~k e m i a .~,~ However, activation of the N-ras gene cannot always be detected in overt leukemias that develop from MDS. Therefore, other oncogenes or antioncogenes presumably play a role in leukemic progression from MDS.
in T) had missense point mutations in the conserved regions of the p53 coding sequence. Furthermore, expression of the wild-type p53 mRNA was not detected in these three patients. The probable absence of normal p53 function in the three cases studied here suggests that alterations in the p53 gene may occasionally play a role in MDS. These three MDS patients with p53 gene mutations and an MDSderived erythroleukemia cell line that we had previously reported to carry a p53 gene mutation showed no N-ras gene mutations, suggesting heterogeneity in the oncogenic mechanism of MDS. MDS. Using reverse transcriptase-polymerase chain reaction (RT-PCR)/single-strand conformation polymorphism (SSCP) analy~is,~.'~ we have examined mutations of the p53 gene in 44 patients with MDS and six patients with overt leukemias that had developed from MDS. The RT-PCR/SSCP analysis has the ability to detect even a point mutation in the coding region of the p53 gene and, moreover, to clearly indicate whether the wild-type p53 gene is expressed. We detected mutations in the p53 coding region in three patients with MDS. Wild-type p53 mRNA was not detected in the bone marrow mononuclear cells from these patients.
MATERIALS AND METHODS
Patients. Bone marrow samples from 50 patients, 13 with refractory anemia (RA), 2 with RA with ringed sideroblasts (RARS), 13 with RA with excess blasts (RAEB), 9 with RA with excess blasts in transformation (RAEB in T), 7 with chronic myelomonocytic leukemia (CMMoL), and 6 with overt leukemia derived from MDS, were collected. Approval was obtained from the Institutional Review Board for these studies. Patients and volunteers were informed that their blood or bone marrow samples were obtained for research purposes, and that their privacy would be protected. Bone marrow mononuclear cells were isolated with density sedimentation. One MDS-derived human erythroleukemia cell line, TF-I,l7 for which we have previously reported the results of RT-PCR/SSCP analysis and sequencing of the p53 gene," was also analyzed for N-ras gene activation.
The RT-PCRfSSCP analysis was performed basically as previously described.' Four p53 cDNA fragments covering the whole p53 gene-coding region were amplified by nested PCRs (first RT-PCR and second PCR). The primers used in the reactions are listed in Table 1 For the SSCP analysis, the S-ends of the second PCR primers were labeled with [y-"P] ATP and T4 polynucleotide kinase (Takara, Kyoto, Japan). The second PCR of 30 cycles (94°C for I minute, 50°C for 1 minute, and 72°C for 2 minutes) was performed using 100 ng each of the labeled primers and the p53 cDNA fragment generated by the first RT-PCR (1 pL of the first RT-PCR solution). The second PCR solution was mixed with 20 vol of 95% fonnamide, 20 mmol/L EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol, and heated at 94OC for 3 minutes. The mixture was quickly chilled on ice, and 2 pL was electrophoresed on a glycerolcontaining nondenaturing gel at room temperature and on glycerolfree nondenaturing gel at 4°C. The p53 cDNA fragments showing aberrant electrophoretic mobility in the SSCP analysis were cloned and sequenced by the dideoxy chain termination method.
RT-PCR/direct sequencing ofN-ras gene. The RT-PCR was performed as described above for the p53 cDNA fragments, except for the primers. Using the nucleotide numbers of the N-ras cDNA sequence published by Hall and Brown:' the sense primers were: RO I, nt -34 to -15; and R12, nt -14 to 6. The antisense primers were: AROI, nt 253 to 244, and AR12, nt 243 to 224. N-ras complementary DNA was synthesized from 1 pg of total RNA using 100 ng of 3'-primer AROI and 200 U of M-MLV reverse transcriptase. The RT reaction solution with 100 ng of 5'-primer ROI and 3 U of Taq polymerase was subjected to 25 cycles of PCR. For direct sequencing, a 500-fold dilution of RT-PCR reaction solution was used in a second 25-cycle PCR with IO ng of 5'-primer R12 and 100 ng of 3'-primer AR12. The resulting single-stranded DNA fragment was purified and sequenced by the dideoxy chain termination method. The end-labeled 5'-primer R12 was used as the sequencing primer.
Sequence analysis of the p53 gene.
RESULTS
In this study, we performed RT-PCR/SSCP analysis o n four p53 cDNA fragments (Extra 5'-, S I -, 3'-, and Extra 3'-side) that cover the entire p53 coding sequence. To make sure of the specificity of these PCR fragments, they were generated by nested PCRs (first RT-PCR and second PCR). T h e resultant D N A fragments were denatured into separate single strands, and each strand assumed a unique conformation during electrophoresis under nondenaturing conditions. Even a single nucleotide substitution can usually be detected, because it alters the threedimensional conformation of the single-stranded D N A fragment and, therefore, its electrophoretic m~bility.'.'~ RT-PCR/SSCP analysis of the p53 gene. Three of the 50 patients were identified to have aberrantly migrating fragments in the 5'-side SSCP analysis performed at room temperature in the presence of 10% glycerol (lanes I, 2, and 3 in Fig I) . These three patients were designated patients I, 2, and 3, respectively. The lanes of these three patients lacked normally migrating fragments. In lanes 1 and 2, three fragments could be detected. Because more than one metastable conformation of a single strand is sometimes allowed in the SSCP analysis,'6 we suppose that two of the three bands are different conformers of the same sequence.
Only these three patients had aberrantly migrating 5'-side SSCP fragments also at 4°C in the absence of 10% glycerol. None of the Extra 5'-, 3 For glycerol or at 4°C in the absence of 10% glycerol (Fig 2) . We furthermore performed the 5'-and 3'-side SSCP analysis on 40 healthy volunteers at room temperature in the presence studied for alterations of the N-rus gene using RT-PCR and direct sequencing. Direct sequence analysis showed the wildtype N-rus cDNA sequence in all four cases (data not shown). of 10% glycerol and found no aberrantly migrating fragments (data not shown).
For patients I, 2, and 3, we cloned the 5'-side p53 cDNA fragments into M 13de-rived vectors and sequenced four independent clones for each fragment to avoid random errors generated by the PCR. Patient l was found to have a missense point mutation at nt 524 (G to A), which results in a change of the encoded amino acid at codon 175 from arginine to histidine (Fig 3, panel 2) . In patient 2, a missense point mutation at nt 410 (T to C) was identified, which generates an amino acid substitution at codon 137 from leucine to proline. Patient 3 had a missense point mutation at nt 569 (C to T) with a predicted amino acid substitution at codon 190 from proline to leucine (Fig  3, panel 4) . The 5'-side p53 cDNA fragments of the three patients were amplified in two additional independent RTPCRs and a total of 12 clones of the fragment was sequenced for each patient. In patients I, 2, and 3, all of the 12 clones had the same mutation as mentioned above. We sequenced normally migrating Extra 5'-, 5'-, 3'-, and Extra 3'-side SSCP fragments from eight other patients (2 with RA, 2 with RAEB, 2 with RAEB in T, 1 with CMMoL, and 1 with overt leukemia from MDS) and confirmed that they contain no p53 mutations (data not shown).
The three patients and the TF-I cell line with a p53 gene mutation were Seqtience unaljsis offhe p53 gene.
RT-PCH/direct sequencing of N-ras gene.

DISCUSSION
Using RT-PCR/SSCP analysis and sequencing, we have identified mutations of the p53 gene in two patients with RAEB and one patient with RAEB in T. Taking into account that we analyzed 44 patients with MDS and six patients with overt leukemias converted from MDS, the incidence of p53 gene mutations in MDS and MDS-derived leukemias is low. It appears that mutations in the p53 gene occur preferentially in more advanced stages of MDS, although the sample numbers here are limited and the difference is not statistically significant. During this study, patient 1 died of infection and patient 2 developed overt leukemia. Patient 3 died of hemorrhage a few months after diagnosis. Table 2 summarizes the diagnosis, karyotype, and p53 gene mutation in these three patients and one MDSderived erythroleukemia cell line that we had previously reported to have a p53 gene mutation.IR Because the effect of sequence alterations on electrophoretic mobility is unpredictable, it is true that some ofthe sequence mutations may not appreciably affect the mobility. However, Orita et all6 reported that single base changes can be detected as mobility shift with SSCP analysis in all I2 arbitrary chosen tumor cell lines that are known to contain mutated H-rus. K-rus, or N-rus. We previously reported that IO normally migrating SSCP fragments had no mutations.' In this study, 
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we sequenced the entire p53 coding region from eight MDS patients negative for the SSCP analyses and confirmed that they contained no mutations. Moreover, we observed normal migration of the 5'-and 3'-side SSCP fragments on 40 healthy volunteers. These findings suggest that the SSCP analysis has relatively high sensitivity and, therefore, usefulness for detecting mutations. When both of the p53 alleles are transcriptionally inactivated in abnormal cells, the RT-PCR will amplify wild-type p53 mRNA from the residual normal cells in the bone marrow samples and the RT-PCR/SSCP analysis cannot detect the p53 gene alteration. Furthermore, if there is far less mutant p53 mRNA than wild-type mRNA in the bone marrow specimen, the SSCP analysis cannot detect the aberrantly migrating fragments. PCR-SSCP analysis was reported to detect a point mutation if more than 10% of the amplified sequence contained the mutation.23 MDS is considered to be a stem cell disorder involving several cell lineages, and morphologic evaluation suggests that not only blast cells but also a considerable part of the other cells in the patient's bone marrow may be of abnormal clone origin. 24 We think, therefore, that most cases analyzed in the present study were free from this problem of normal cell contamination.
Although we performed RT-PCR/SSCP analysis on the entire p53 coding sequence in this study, the detected mutations were all missense point mutations located within or near the four regions highly conserved during e v o l~t i o n .~-~~ The G to A transition at codon 175 presented in patient 1 is one of the most frequent mutations of the p53 gene.25 This transition, which occurs at a CpG dinucleotide, a well-known hot spot for spontaneous mutations, was previously found in many cases of colon, breast, and brain tumor^.^^^^ The same mutation was also detected in human leukemia and lymphoma cell lines, KY82 1,18 CEM,26 and CW67tX8 To our knowledge, the transition at codon 137 in patient 2 is a novel mutation of the p53 gene. A different mutation at the codon was reported in a case of sarcoma.25 Although a missense mutation at codon 190 in patient 3 is novel, we have previously reported a three-base deletion at this codon.7 The MDSderived leukemia cell line had a deletion of a T nucleotide, causing a frame shift in the p53 coding sequence." Therefore, these four mutations may affect the normal function of the p53 protein product. In these patients and the cell line, the RT-PCR/SSCP analysis detected no normally migrating fragments. In each of the three patients, all 12 clones of the 5'-side p53 cDNA fragment contained the identical mutation. These results suggest that only mutant p53 mRNA was expressed in the bone marrow mononuclear cells of the patients and the MDS-derived erythroleukemia cell line. Furthermore, loss of chromosome 17p coupled with the p53 gene mutation in patient 3 supports this probability. Although the incidence of p53 gene mutations seems low in MDS patients, the probable inactivation of both p53 alleles in the four examples suggests that alterations in the p53 gene may play a role in a small fraction of cases of MDS.
All the p53 gene mutations detected here were in association with several chromosomal abnormalities. The five MDS patients with mutations in the p53 gene reported by Jonveaux et alZ7 also showed variable cytogenetic abnormalities. Recently emerging evidence suggests that normal p53 monitors the integrity of the genome and, if DNA is damaged, switches off r e p l i c a t i~n .~~,~~ On the contrary, tumor cells without normal p53 cannot carry out this arrest. Therefore, they are genetically less stable and accumulate chromosomal abnormality. This new view suggests that the mutations in the p53 gene may not be a mere result of multiple chromosomal changes, but instead are involved in the genomic instability and progression of some part of MDS.
Both activation of oncogene(s) and inactivation of tumor suppressor gene(s) are considered to be necessary for tumorigenesis in some human malignancies. In a genetic model for colorectal cancer, inactivation of the p53 gene is thought to be one of multiple steps to the fully tumorigenic phenotype.30 Although MDS is a syndrome that comprises heterogeneous disorders, at least some cases of MDS are considered to be clonal diseases caused by genetic changes. We previously reported the significance of mutations in the N-rus gene in the progression from MDS to overt leukemia^:^ and other groups showed fms gene mutations in MDS." We detected no Nrus gene activation in the three MDS patients and the MDSderived leukemia cell line with p53 gene mutations in this study. The results suggest that MDS is heterogeneous not only in its phenotype but also in the molecular mechanism of its genesis and progression. More extended and detailed study is necessary to understand the molecular basis of MDS development.
